SCHEMBL4255698

SCHEMBL4255698

C=CCN1C(=O)C2(NC(=O)NC2=O)c2cc(C)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.55
GAA P10253 3/20 0.41
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
CNR1 P21554 3/20 0.40
KDM4E B2RXH2 2/20 0.39
AKR1B1 P15121 2/20 0.39
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALPL P05186 1/20 0.38
ALPI P09923 1/20 0.38
ALPG P10696 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
TSHR P16473 1/20 0.35
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4266330 0.87 POLB (0.41) POLBALDH1A1SMN1; SMN2CNR1KDM4E
SCHEMBL4267235 0.85 AKR1B1 (0.50) POLBGAAALDH1A1CNR1KDM4E
SCHEMBL4261414 0.82 ALDH1A1 (0.53) POLBGAAALDH1A1USP2CNR1
SCHEMBL4258238 0.82 ADAMTS5 (0.39) POLBALDH1A1KDM4EAKR1B1MAPT
SCHEMBL4255513 0.82 PTGDR2 (0.40) POLBGAAALDH1A1AKR1B1MAPT
SCHEMBL4255794 0.81 AKR1B1 (0.46) POLBGAAALDH1A1CNR1KDM4E
SCHEMBL4174404 0.81 AKR1B1 (0.39) POLBGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL4255427 0.80 MAPT (0.45) GAAALDH1A1SMN1; SMN2CNR1KDM4E
SCHEMBL4164829 0.80 AKR1B1 (0.41) POLBALDH1A1SMN1; SMN2CNR1AKR1B1
SCHEMBL4261411 0.80 AKR1B1 (0.38) POLBALDH1A1SMN1; SMN2AKR1B1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 US claimed
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV2, TRPV3 POLB 4847/4885GAA 4271/4885ALDH1A1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.